An interventional study of Pitavastatin and Pitavastatin plus Ezetemibe in Dyslipidemias and Atherosclerotic Cardiovascular Disease, sponsored by Yonsei University. Recruiting at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Yonsei University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pitavastatin in Dyslipidemias — 2 open to participants now, 3 under way, none of them phase 3. pitavastatin · Dyslipidemias.
Among the 21 studies testing pitavastatin in Dyslipidemias, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 2 with no phase, and was the 20th registered.
1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →2 of the 21 studies testing pitavastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:
Eccogene · Sites in Australia
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 250 is above the median of 100 across 988 interventional studies indexed under Dyslipidemias.
Median enrollment 252 across the 21 interventional studies. Of the 13 that completed or were terminated, 12 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 21 have an industry lead sponsor. The 10 most frequent:
Yonsei University is the lead sponsor of 1,421 studies on the registry; 241 are open to participants now.
13 studies in Dyslipidemias by Yonsei University: 5 open now, 6 under way, none of them phase 3. Of 6 finished, 0 (0%) have results posted.
Among the 13 studies in Dyslipidemias by Yonsei University, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 5 with no phase, and was the 8th registered.
Yonsei University’s Dyslipidemias studies by the year they started, since 2015.
1 of the studies testing pitavastatin in Dyslipidemias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07726368EccogeneStudy of ECC4703 With Sulfasalazine and Pitavastatin | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pitavastatin in Dyslipidemias, from their registry updates:
Among Yonsei University’s 13 in Dyslipidemias:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to investigate the effect of pitavastatin or pitavastatin and ezetimibe combination therapy on glucose metabolism compared to atorvastatin in patients with atherosclerotic cardiovascular disease with metabolic syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pitavastatin 4mg group
Drug: Pitavastatin
Pitavastatin 4 mg Ezetimibe 10 mg combined administration group
Drug: Pitavastatin plus Ezetemibe
Atorvastatin 40 mg administration group
Drug: Atorvastatin
Pitavastatin 4 mg will be given.
Pitvastatin 4 mg plus ezetemibe 10 mg will be given.
Atorvastatin 40 mg will be given.
Change form baseline homeostatic model assessment for insulin resistance (HOMA-IR) at 24 weeks
Changes of homeostatic model assessment for insulin resistance (HOMA-IR) form baseline to 24 weeks will be compared among the three groups.
Time frame: At 24 weeks
Proportion of fasting glucose ≥100 mg/dL
Time frame: At 24 weeks
Proportion of HbA1C ≥6.5%
Time frame: At 24 weeks
Proportion of new-onset diabetes mellitus
Time frame: At 24 weeks
Changes of HOMA-β at 24 weeks
Time frame: At 24 weeks
Changes of fasting glucose at 24 weeks
Time frame: At 24 weeks
Changes of insulin at 24 weeks
Time frame: At 24 weeks
Changes of HbA1c at 24 weeks
Time frame: At 24 weeks
Changes of triglyceride at 24 weeks
Time frame: At 24 weeks
LDL-cholesterol change at 24 weeks
Time frame: At 24 weeks
HDL-cholesterol change at 24 weeks
Time frame: At 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Feb 2028, 56 months after the start.
Of 194 non-industry interventional studies with no phase under Dyslipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 56 months is above that.
Counting every sponsor, half of 205 studies reached it within 16 months; a quarter within 8 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion May 2027 → Feb 2028 and completion Jun 2027 → Aug 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin